神经基因公司 NGNE

Dr. McMinn has served as Chief Executive Officer and Executive Chair of our Board since December 2023, and as Founder, Chief Executive Officer and a member of the Board of Directors of Neurogene OpCo since January 2018. Prior to founding Neurogene, she served as Chief Business and Strategy Officer of Intercept Pharmaceuticals, Inc. (formerly Nasdaq: ICPT, until its acquisition by Alfasigma S.p.A.), a biopharmaceutical company dedicated to the treatment of patients with serious liver disease, from April 2014 to December 2017. Prior to her operational experience, Dr. McMinn was an award-winning biotechnology analyst, with 13 years of experience at firms such as Bank of America Merrill Lynch, Cowen and Company and Piper Jaffray. Dr. McMinn has served on the board of directors of Everyone Medicines since 2021, and prior to that the non-profit Everyone Foundation from 2019 to 2021. Dr. McMinn received her B.A., magna cum laude, from Cornell University and her Ph.D. from The Scripps Research Institute, and was awarded a Post-Doctoral Miller Fellowship at the University of California, Berkeley.

Effective April 20, 2026, Ms. Mikail was appointed to the Company's Board of Directors as a Class II director, with a term expiring at the 2028 annual meeting of stockholders. Ms. Christine Mikail Cvijic served as our President and Chief Financial Officer since December 2023, and as President and Chief Financial Officer of Neurogene OpCo since September 2019 and as a member of the board of directors of Neurogene OpCo since December 2023. In her role, Ms. Mikail leads Corporate Strategy and Business Development, Portfolio Management, Operations, and Finance. Ms. Mikail brings over two decades of experience supporting biotechnology and pharmaceutical companies in corporate strategy and business development, operations, legal and finance capacities. Prior to Neurogene, Ms. Mikail was Chief Administrative Officer and Head of External Business Development/Alliance Management and General Counsel at Axovant Sciences (which became Sio Gene Therapies Inc. (OTCMAKTS: SIOX)) from March 2015 to March 2017, where she was an integral member of the team that raised $362 million in the company's initial public offering. Prior to Axovant, she held a variety of senior executive positions at NPS Pharmaceuticals, Inc., Dendreon Corporation, Eli Lilly and Company, and ImClone Systems. Ms. Mikail developed her life sciences focus as a corporate and securities lawyer at the international law firms of Reed Smith LLP and Wilmer Cutler Pickering Hale and Dorr LLP. Ms. Mikail received her B.A., cum laude, from Rutgers University and her J.D. from Fordham University School of Law in New York.

Dr. Jordan has served as our Chief Medical Officer since January 2024. Prior to Neurogene, Dr. Jordan served as Chief Medical Officer of Homology Medicines, Inc. (formerly Nasdaq: FIXX) from March 2023 to August 2023, where she was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company's pipeline of gene therapy and gene editing candidates for rare diseases, Senior Vice President, Head of Clinical Development and Operations from February 2022 to March 2023 and Vice President, Clinical Development from May 2021 to February 2022. Prior to Homology, Dr. Jordan served as Senior Director, Global Clinical Development at Cerevel Therapeutics, LLC, a pharmaceutical company, from August 2019 to April 2021, where she was responsible for leading clinical development and operations. Prior to Cerevel, she served as Executive Director, Global Clinical Development at Avanir Pharmaceuticals, Inc., a pharmaceutical company, from March 2019 to July 2019, and Senior Director, Global Clinical Development at Avanir from April 2017 to February 2019, where she was also responsible for leading clinical development and operations. Prior to joining industry, Dr. Jordan was a Clinical Instructor of Medicine at Harvard Medical School, treating patients at Massachusetts General Hospital (MGH). Dr. Jordan holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in internal medicine at MGH, Harvard Medical School.

Rohan Palekar has served as a member of our Board since March 2022. Mr. Palekar served as Chief Executive Officer of 89bio, Inc., a biopharmaceutical company, from June 2018 until January 2026 and as a member of the board of directors from June 2018 until October 2025 when the company was acquired by Roche. Prior to 89bio, Mr. Palekar held various positions at Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, including the role of President and Chief Executive Officer of Avanir from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Prior to the acquisition, Mr. Palekar served as Executive Vice President and Chief Operating Officer in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Mr. Palekar has also held prior executive roles, including Chief Commercial Officer for Medivation, Inc., and various senior commercial and strategic management roles during his 16 years at Johnson & Johnson (NYSE: JNJ). Mr. Palekar served as a trustee for Aim High for High School, a non-profit educational institution, from 2018 until 2023 and chair of the board of trustees from 2021 to 2023. Mr. Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his L.L.B. from the University of Mumbai. Mr. Palekar is also a certified Chartered Accountant and a Cost and Management Accountant.

Dr. Baffi has served as a member of our Board since December 2023 and served as a member of the board of directors of Neurogene OpCo from September 2020 to December 2023. Dr. Baffi is a Venture Partner at Samsara BioCapital (Samsara), an investment company focused on the life sciences industry, which he joined in March 2021. Dr. Baffi had a 23-year tenure at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company, from May 2000 to March 2023, where he served as President of Global Manufacturing & Technical Operations from 2018 to 2020, was responsible for overseeing manufacturing, process development based on the baculovirus system, quality, logistics, engineering and analytical chemistry, and led the building of one of the first gene therapy manufacturing facilities of its kind, before he became Senior Advisor to the Chairman and Chief Executive Officer in 2021. Prior to BioMarin, Dr. Baffi served 14 years in a number of increasingly senior positions at Genentech, Inc., primarily in the functional area of quality control, as a Research Scientist at Cooper BioMedical, Inc. and as a Post-Doctoral Fellow at the Becton Dickinson Research Center. Dr. Baffi has contributed to the approval and commercial success of 28 products. Since 2024, Dr. Baffi has served as a member of the board of directors of Neuvivo, Inc., a venture-backed biotechnology company. Dr. Baffi is an emeritus member of the science advisory board of the National Institute for Bioprocessing Research & Training. Dr. Baffi served as a member of the board of directors of Mosaic ImmunoEngineering Inc. (OTMTKS: CPMV), a biotechnology company, from June 2021 until August 2025, and Bionic Sight, Inc., a biotechnology company, from 2020 until 2024. Dr. Baffi received his Ph.D., M. Phil. and B.S. in biochemistry from the City University of New York and his M.B.A. from Regis University.

Dr. Freedland has served as a member of our Board since December 2023 and as Lead Independent Director since January 2026. He also served on the board of directors of Neurogene OpCo from February 2019 to December 2023. Dr. Freedland is an independent consultant for biopharmaceutical companies. He was previously a Partner at Samsara BioCapital (Samsara), an investment company focused on the life sciences industry, from October 2017 until May 2025. Dr. Freedland has over 20 years of experience, leading multiple successful life science investments in his role. Prior to Samsara, Dr. Freedland was a Principal at Sofinnova Ventures, a biopharmaceutical venture capital firm, where he focused on biopharmaceutical investments. He played a central role in Sofinnova's investments in Civitas Therapeutics, Inc. (acquired by Acorda Therapeutics, Inc.), Principia Biopharma, Spark Therapeutics, Inc. (acquired by Roche), Ziarco Pharma Ltd. (acquired by Novartis AG), and ZS Pharma, Inc. (acquired by AstraZeneca plc). Prior to Sofinnova, Dr. Freedland was a Principal at Novo A/S. Before his transition to healthcare investing, Dr. Freedland was a Vice President in the healthcare investment banking practice at Morgan Stanley. Prior to transitioning to life sciences finance, Dr. Freedland worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. Dr. Freedland served on the board of directors of Jiya Acquisition Corp. from November 2020 to November 2022. Dr. Freedland has also served on the board of directors of multiple private companies. Dr. Freedland received his Ph.D. in Pharmacology from Wake Forest University School of Medicine, his M.B.A. from the Kellogg School of Management and his B.A. in Psychology and Religious Studies from Connecticut College.

Mr. Woods has served as a member of our Board since December 2023. Since April 2025, Mr. Woods has been the Chief Operating Officer of Scholar Rock, Inc., a biopharmaceutical company focused on the discovery, development and delivery of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Prior to his role at Scholar Rock, Mr. Woods was an advisor to the board of directors of argenx SE (Nasdaq: ARGX), a biopharmaceutical company, from March 2023 until April 2025, and served as Chief Operating Officer of argenx SE from April 2018 to March 2023. Mr. Woods has over 30 years of experience in the biopharmaceutical industry, including senior roles at Alexion Pharmaceuticals, Inc., where among other things he led the launch of Soliris in atypical hemolytic uremic syndrome. Prior to Alexion, Mr. Woods held various positions of increasing responsibility within Roche, Amgen Inc. and Eisai Co., Ltd., over a span of 20 years. Mr. Woods has served on the board of directors of TScan Therapeutics, Inc. (Nasdaq: TCRX) since December 2023, and also served on the boards of X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) from October 2023 until April 2025 and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) from December 2023 until April 2025. Mr. Woods received his B.S. in Marketing from Florida State University.

Dr. Noonberg has served as a member of our Board since August 2019. Dr. Noonberg has over 20 years of industry experience leading development programs from discovery to commercialization across a range of indications, and has served as the Chief Medical Officer of AbCellera Biologics Inc. (Nasdaq: ABCL), a clinical-stage biotechnology company focused on anti-body based medicines in endocrinology, women's health, immunology and oncology, since September 2025. Prior to AbCellera, from January 2023 to August 2025, Dr. Noonberg served as Chief Medical Officer of Metagenomi, Inc. (Nasdaq: MGX), a next-generation gene editing biotechnology company, and from September 2020 to September 2022, as the Chief Medical Officer of Maze Therapeutics, a human-genetics driven research and development company. Other executive roles have included Chief Medical Officer of Nohla Therapeutics Inc., Chief Medical Officer of Prothena Corporation plc (Nasdaq: PRTA), Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN), and Senior Vice President of Early Development at Medivation, Inc. Dr. Noonberg also previously served as a member of the board of directors of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company, from May 2023 to November 2024, and on the board of directors of Protagonist Therapeutics, Inc (Nasdaq: PTGX), a biopharmaceutical company, from December 2017 to May 2023. Dr. Noonberg received her M.D. from the University of California, San Francisco, her Ph.D. in Bioengineering from the University of California, Berkeley, and her B.S. in Engineering from Dartmouth College. She is a board-certified internist and completed her residency at Johns Hopkins Hospital.

Effective April 20, 2026, Ms. Shafer was appointed Chief Commercial Officer of Neurogene Inc. Ms. Christy Shafer has more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for rare neurological diseases. Prior to joining Neurogene, Ms. Shafer most recently served as Senior Vice President and General Manager, North America, at Avidity Biosciences, where she built and led the company's North America commercial organization in advance of its first U.S. product launches. Previously, she served as Chief Commercial Officer at Marinus Pharmaceuticals, where she built and led the commercial organization and launched Ztalmy, the first approved therapy for seizures associated with CDKL5 deficiency disorder, which led to Marinus Pharmaceuticals' acquisition by Immedica Pharma. Earlier in her career, Ms. Shafer held leadership roles of increasing responsibility at Alexion Pharmaceuticals, Pacira Pharmaceuticals, and Sanofi Biosurgery, formerly Genzyme. Ms. Shafer holds a Bachelor of Life Science degree in Cell and Molecular Biology and Genetics from the University of Maryland, College Park, and completed postbaccalaureate studies in immunology and pharmacology.

Dr. Cobb has served as our Chief Scientific Officer since December 2023, and as Chief Scientific Officer of Neurogene OpCo since January 2019. Dr. Cobb brings more than 20 years of experience in translational neuroscience. His expertise is focused on developing genetic therapies for severe neurological and neurodevelopmental disorders. Dr. Cobb leads Neurogene's scientific research, the development of scientific strategy to support Neurogene's existing and growing gene therapy portfolio, and efforts to identify novel technologies that complement Neurogene's pipeline. In addition to his role at Neurogene, Dr. Cobb has been a director of Stuart Cobb Consulting LTD, a scientific consultancy firm since December 2018 and has led a genetic therapy research laboratory as principal investigator within the Medical School at the University of Edinburgh since November 2017 where he currently serves as the Chair of Translational Neuroscience. Prior to these roles, Dr. Cobb was an independent principal investigator and laboratory head from October 1999 to October 2017 and was previously head of the Centre for Neuroscience at the University of Glasgow. He also previously worked at Inveresk Research International, a contract research organization, from June 1987 to September 1989. Dr. Cobb received his B.Sc. in Pharmacology from the University of Glasgow and Ph.D. (D.Phil.) in Neuroscience from the University of Oxford.